Gouvernance Eli Lilly and Company

LLY

US5324571083

Produits pharmaceutiques

Marché Fermé - Nyse Autres places de cotation 22:00:02 16/05/2025			Varia. 5j.	Varia. 1 janv.
757,39 ^USD	+3,50 %		+3,11 %	-1,89 %

16/05	La FDA américaine autorise le premier test sanguin de dépistage de la maladie d'Alzheimer	RE
16/05	La FDA américaine autorise le premier test sanguin pour détecter la maladie d'Alzheimer	RE

Comité Exécutif: Eli Lilly and Company

Dirigeant

Fonctions occupéesDepuis

David Ricks

57 ans

Chief Executive Officer	01/01/2017
President	01/01/2017

Diogo Rau

50 ans

Chief Tech/Sci/R&D Officer

17/05/2021

Eric Dozier

58 ans

Human Resources Officer

31/08/2022

Ruth Gimeno

President

David Hyman

Chief Tech/Sci/R&D Officer

16/10/2023

Donald Zakrowski

Comptroller/Controller/Auditor

01/11/2012

Daniel Skovronsky

51 ans

Chief Tech/Sci/R&D Officer

Lucas Montarce

48 ans

Director of Finance/CFO

09/09/2024

Anat Hakim

55 ans

General Counsel	03/02/2020
Corporate Secretary	-

Composition du Conseil d'Administration: Eli Lilly and Company

Administrateur

ComitésDepuis

David Ricks

57 ans

Compensation Committee

12/04/2018

Ralph Alvarez

69 ans

Audit Committee
Compensation Committee Chair
Compensation Committee
Governance Committee
Nominating Committee

Gabrielle Greene-Sulzberger

64 ans

Audit Committee	25/01/2021
Governance Committee
Nominating Committee	01/12/2018

Mary Lynne Hedley

62 ans

Governance Committee Chair	16/08/2019
Nominating Committee Chair	16/08/2019
Audit Committee	23/02/2021

Jamere Jackson

55 ans

Governance Committee	01/10/2016
Audit Committee Chair	01/10/2016

Juan Luciano

63 ans

Compensation Committee
Governance Committee Chair

Jon Moeller

60 ans

Audit Committee	01/12/2024
Governance Committee	01/12/2024

William Kaelin

67 ans

Governance Committee

Kimberly Johnson

52 ans

Compensation Committee

16/02/2021

Jon Fyrwald

64 ans

Compensation Committee

Katherine Baicker

53 ans

Director/Board Member	12/12/2011
Independent Dir/Board Member	12/12/2011

Dernières Nominations: Eli Lilly and Company

De l'insuline à l'Ozempic, histoire des PDG de Novo Nordisk	16/05	RE
Le PDG de Novo Nordisk démissionne	16/05	RE
INSTANT VIEW - Le fabricant de Wegovy, Novo Nordisk, limoge son PDG alors que la concurrence s'intensifie sur le marché des médicaments contre l'obésité	16/05	RE
INSTANT VIEW - Départ surprise du PDG de Novo Nordisk après des revers sur le marché des produits amaigrissants	16/05	RE
Novo Nordisk se sépare de son dirigeant sur fond de concurrence accrue	16/05	RE
Novo Nordisk se sépare de son dirigeant sur fond de concurrence accrue	16/05	RE
Le directeur général de Novo Nordisk va quitter ses fonctions	16/05	RE

Plus d'Actualités

Anciens Dirigeants et Administrateurs: Eli Lilly and Company

Insider

Fonctions occupées

DepuisJusqu'au

Kathi P. Seifert

Director/Board Member	01/01/1995	03/05/2021
Independent Dir/Board Member	01/01/1995	03/05/2021

Ellen Marram

Director/Board Member	01/01/2002	01/05/2019
Chairman	09/05/2013	08/07/2013
Independent Dir/Board Member	01/01/2012	01/05/2019

John Lechleiter

Director/Board Member	01/01/2005	01/01/2009
Chief Executive Officer	01/04/2008	31/12/2016
Chairman	01/01/2009	31/05/2017
Chief Operating Officer	01/01/2005	01/04/2008
General Counsel	01/01/1994	01/01/1998
Corporate Officer/Principal	01/01/1998	01/01/2005
President	01/01/2005	31/12/2016

Franklyn Prendergast

Director/Board Member	01/04/1995	01/01/2017
Independent Dir/Board Member	01/04/1995	01/01/2017

Derica Rice

Comptroller/Controller/Auditor	01/01/2003	01/01/2006
Director of Finance/CFO	01/01/2006	01/01/2017

Karen Horn

Director/Board Member	01/01/1987	02/05/2016
Independent Dir/Board Member	15/04/2011	02/05/2016

Win Bischoff

Director/Board Member	01/04/2000	05/05/2014
Independent Dir/Board Member	25/04/2011	05/05/2014

Robert A. Armitage

Director/Board Member	26/04/2011	05/05/2011
General Counsel	01/11/1999	31/12/2012

Arnold Hanish

Comptroller/Controller/Auditor

01/01/1984

01/12/2012

Martin Feldstein

Director/Board Member	01/01/2002	04/06/2012
Independent Dir/Board Member	15/04/2011	04/06/2012

Anne Nobles

Director/Board Member	05/05/2011	07/09/2011
General Counsel	01/01/1990	01/01/2012

Frank M. Deane

Director/Board Member	05/05/2011	06/05/2011
Corporate Officer/Principal	01/01/1986	01/01/2012

Alex Michael Azar

Public Communications Contact	01/06/2007	01/04/2009
Corporate Officer/Principal	01/04/2009	01/12/2011

David Bredt

Corporate Officer/Principal

01/01/2004

01/01/2011

Gino Santini

Corporate Officer/Principal

01/01/1990

01/12/2010

Steven Paul

Chief Tech/Sci/R&D Officer

01/04/1993

01/02/2010

Anthony John Murphy

Human Resources Officer

01/01/1980

30/04/2009

J. Michael Cook

Director/Board Member

01/01/2005

20/04/2009

Deirdre Connelly

Human Resources Officer	01/01/2003	01/06/2005
Corporate Officer/Principal	01/06/2005	30/01/2009

Charles E. Golden

Director of Finance/CFO

01/03/1996

30/04/2006

John Edward Victor Rose

Director/Board Member

14/10/2005

Steven C. Beering

Director/Board Member

18/04/2005

Bryan Dunnivant

Chief Operating Officer

01/01/2001

31/12/2004

Vanessah Ng

Corporate Officer/Principal

31/12/2004

Webster Dunbar

Chief Tech/Sci/R&D Officer	01/01/1999	01/01/2003
Corporate Officer/Principal	01/01/2003	01/09/2004

Joseph Zakrzewski

Corporate Officer/Principal

01/01/2003

01/01/2004

Pedro Granadillo

Human Resources Officer	01/01/1970	01/01/2004
Corporate Officer/Principal	01/01/1970	01/01/2004

Scott Priebe

Corporate Officer/Principal

31/12/2003

Alan Breier

Chief Tech/Sci/R&D Officer

01/08/2003

August M. Watanabe

Corporate Officer/Principal

01/06/2003

Brett L. Schmidli

Corporate Officer/Principal

01/01/1992

01/01/2002

Jerome H. Fleisch

Corporate Officer/Principal

01/01/1974

31/12/2001

Stephen W. Kaldor

Corporate Officer/Principal

01/06/1989

31/12/2001

David A. Broecker

Corporate Officer/Principal

01/08/1985

01/01/2001

George Fisher

Director/Board Member

01/01/2000

John T. Boris

Corporate Officer/Principal

02/01/1988

01/01/1998

Lionel Carnot

Corporate Officer/Principal

01/01/1995

01/01/1997

Alfred G. Gilman

Director/Board Member	01/01/1995	-
Independent Dir/Board Member	15/04/2011	-

James Cornelius

Director/Board Member	01/01/1983	01/01/1995
Director of Finance/CFO	01/01/1983	01/01/1995

Paul F. Banta

General Counsel

01/06/1987

01/01/1995

Ron D. Henriksen

Corporate Officer/Principal

01/01/1971

01/01/1994

B. Jack Miller

Human Resources Officer

01/01/1968

31/12/1987

Simon Li

Corporate Officer/Principal

Ronald A. Matricaria

Corporate Officer/Principal

Anton G. Gueth

Corporate Officer/Principal

Kurt Wheeler

Corporate Officer/Principal

Mike Peterson

Corporate Officer/Principal

Rafik H. Bishara

Corporate Officer/Principal

Michael Sherman

Corporate Officer/Principal

James B. Lootens

Corporate Secretary

Stephen Andrade

Corporate Officer/Principal

Eric E. Easom

Corporate Officer/Principal

Dennis W. White

Corporate Officer/Principal

Paul A. Hyslop

Corporate Officer/Principal

P. Reed Maurer

Corporate Officer/Principal

Pat O'Day

Corporate Officer/Principal

Stephen E. Butts

Corporate Officer/Principal

Seth D. Goldblum

Corporate Officer/Principal

John Barnard

Corporate Officer/Principal

Wei Zhang

Corporate Officer/Principal

James F. White

Corporate Officer/Principal

William D. Huse

Corporate Officer/Principal

Jim R. Baumgardt

Director/Board Member

Todd F. Kirschner

Corporate Officer/Principal

Aaron Davidson

Corporate Officer/Principal

Fredric Cohen

Corporate Officer/Principal

Edward S. Dunn

Corporate Officer/Principal

Robert W. McLaughlin

Corporate Officer/Principal

Donald C. Aroborgast

Corporate Officer/Principal

Molly Montgomery

Corporate Officer/Principal

Michael Heffernan

Corporate Officer/Principal

John R. Uhrin

Corporate Officer/Principal

Jack Steele

Corporate Officer/Principal

Vincent J. Gurnari

Sales & Marketing

Dale M. Edgar

Director/Board Member

Erin Markey

Corporate Officer/Principal

Chen-Ming Yu

Corporate Officer/Principal

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	26
Femme	9

Dont comité exécutif

Homme	7
Femme	2

Dont Administrateurs

Homme	9
Femme	2

Révisions

Révisions CA 1 an

Révisions CA 4 mois

Révisions CA 1 mois

Révisions BNA 1 an

Révisions BNA 4 mois

ESG MSCI

ESG

ESG : Environnement

ESG : Social

ESG : Gouvernance

ESG : Polémique

ESG : Controverses Ethiques

ESG : Controverses sur les droits de l'Homme

ESG : Controverses Subventions fiscales

ESG : Conforme à la finance Islamique

Eli Lilly and Company figure parmi les principaux groupes pharmaceutiques mondiaux. Le CA par domaine thérapeutique se répartit comme suit : - endocrinologie (65,5%) : produits pour le traitement de l'ostéoporose, du diabète et des problèmes de croissance ; - oncologie (19,4%) ; - maladies immunitaires (9,8%) ; - neurologie (3,3%) : essentiellement médicaments destinés au traitement de la dépression et de la schizophrénie ; - autres (2%). La répartition géographique du CA est la suivante : Etats-Unis (67,4%), Europe (15,4%), Japon (4%), Chine (3,7%) et autres (9,5%).

Employés

47 000

Secteur

Produits pharmaceutiques

Agenda

07/08 - Q2 2025 Publication de résultats

Plus d'informations sur la société